FIGO 2023 staging for endometrial cancer, when, if it is not now?

IF 7.6 1区医学 Q1 ONCOLOGY

European Journal of Cancer Pub Date : 2024-11-05 DOI:10.1016/j.ejca.2024.115115

Xavier Matias-Guiu , Sigurd Lax , Maria Rosaria Raspollini , Jose Palacios , Wenxin Zheng , Congrong Liu , Louise de Brot , Leonardo Lordello , David Hardisson , David Gaffney , David Mutch , Giovanni Scambia , Carien L. Creutzberg , Christina Fotopoulou , Jonathan S. Berek , Nicole Concin

引用次数: 0

Abstract

Incorporation of pathological and (not mandatory) molecular features into the new FIGO 2023 staging system has generated some controversy. Several validations have been published recently that demonstrated the higher prognostic precision of FIGO 2023 compared to the previous FIGO 2009 scheme. In the present article, the authors want to respond to some concerns that were raised by some pathologists and clinicians.

查看原文本刊更多论文

FIGO 2023 子宫内膜癌分期，如果不是现在，是何时？

在新的 FIGO 2023 分期系统中纳入病理特征和（非强制性的）分子特征引起了一些争议。最近发表的一些验证结果表明，与之前的 FIGO 2009 方案相比，FIGO 2023 的预后精确度更高。在本文中，作者希望对一些病理学家和临床医生提出的疑虑做出回应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Journal of Cancer 医学-肿瘤学

CiteScore

11.50

自引率

4.80%

发文量

953

审稿时长

23 days

期刊介绍： The European Journal of Cancer (EJC) serves as a comprehensive platform integrating preclinical, digital, translational, and clinical research across the spectrum of cancer. From epidemiology, carcinogenesis, and biology to groundbreaking innovations in cancer treatment and patient care, the journal covers a wide array of topics. We publish original research, reviews, previews, editorial comments, and correspondence, fostering dialogue and advancement in the fight against cancer. Join us in our mission to drive progress and improve outcomes in cancer research and patient care.